Bcl-2 inhibits apoptosis from a variety of stimuli, and a Bcl-2-binding protein BAG-1 also functions in protection from apoptosis in concert with Bcl-2. Here, we provide evidence that prolonged cell survival introduced by overexpression of Bcl-2 or BAG-1 proteins strongly promotes experimental pulmonary metastasis of melanoma B16-BL6 cells. In murine melanoma cell line B16-BL6, gene transfer-mediated expression of the Bcl-2 or BAG-1 led to prolonged cell survival against serumstarved apoptosis in vitro. The Bcl-2-expressing B16 cells, B16-Bcl-2 and the BAG-1-expressing B16 cells, B16-BAG-1 strongly enhanced pulmonary metastasis in allogenic BALB/c nude mice and whole lung weights were increased by 2.4-fold and 1.4-fold, respectively, compared with control transfectants, suggesting that Bcl-2 is a stronger positive modulator of metastasis. When the viable B16-Bcl-2 and control transfectants were injected subcutaneously into BALB/c nude mice, the colony numbers of pulmonary metastasis of the B16-Bcl-2 transfectant increased by 5.6-fold compared with the control transfectants. These enhanced metastatic potentials in the B16-Bcl-2 and the B16-BAG-1 transfectants were well correlated with anti-cell death activity against serum-starvation and enhanced cell viability on limiting dilution. Analysis of the transfectants however revealed that their growth rates, invasive ability and cell motility were not signi®cantly altered by overexpression of either Bcl-2 or BAG-1 proteins. Taken together, these studies demonstrate that prolonged cell survival is a crucial factor to promote metastasis of melanoma, thereby contributing to tumor progression.
Introduction
Apoptosis is a crucial event in a wide variety of biological processes including embryogenesis, organ development, immune system and homeostatic system. All of these events are tightly regulated to maintain appropriate cell numbers in the body by balancing cell production and cell death, and its imbalance is likely to lead to the abnormal cell growth. In this context, disturbances of physiological apoptosis can contribute to the cancer development. Bcl-2 gene, for example, was originally identi®ed by molecular analysis of the chromosomal translocation t(14;18)(q32;q21) found in follicular lymphomas (Tsujimoto et al., 1985) and B-cell lymphomas are frequently found in the transgenic mice overexpressing Bcl-2 product (McDonnell et al., 1989) . Considering that Bcl-2 functions in suppression of apoptosis induced by a variety of stimuli such as starvation of growth factors, loss of cell attachment to extracellular matrix, Fas-stimulation, and cytotoxic T-cell killing (Reed, 1994) , inhibition of apoptosis may promote oncogenesis in broad cell types. Consistently, recent studies have revealed that overexpression of Bcl-2 occurs frequently in human cancers and its expression is associated with tumor progression (McDonnell et al., 1992) .
To date, many other Bcl-2 family genes have been identi®ed that participate in either protection from or promotion of apoptosis. Members of the Bcl-2 protein family share at least one of several conserved regions BH1 to BH4 and can interact with themselves or other molelcules (Sato et al., 1994; Zha et al., 1996) . A novel Bcl-2-binding protein BAG-1 can prolong cell survival in concert with Bcl-2 (Takayama et al., 1995) . Since BAG-1 has no conserved regions (BH1-BH4) in common with Bcl-2 family, BAG-1 may have a unique function in protection from apoptosis.
Cancer metastasis and invasion remain the most formidable obstacles in cancer therapy. The metastatic process consists of multiple steps and its regulation is extremely complicated (Fidler, 1990; Nicolson, 1989) . To gain metastatic potential, cancer cells must undergo changes in several biological activities, including their dependence on local growth factors, ability to survive in the absence of integrin signals, increase of cell motility, and increase of invasive ability (Fidler, 1990; Partin et al., 1989; . Recently, several reports have proposed that prolonged cell survival may confer a bene®t for metastasis to cancer cells (Xie et al., 1995; Glinsky and Glinsky, 1996) . After detachment of cancer cells from primary origin, they may confront a variety of obstacles, which may lead to their apoptosis. However, there is no direct experimental evidence linking apoptosis and metastasis. We report here that overexpression of Bcl-2 or BAG-1 promotes metastasis of murine B16 melanoma cells. Their increased metastatic potential is associated with neither increased invasive activity nor enhanced cellular growth, but is well correlated with the ability of Bcl-2 to protect these cells from apoptosis. Thus, our data indicates a linkage of cancer cell survival to the metastatic potential.
Results

Growth of B16-BL6 expressing Bcl-2 or BAG-1
A cDNA pB4 encoding full-length Bcl-2 protein (Tsujimoto and Croce, 1986) or a cDNA encoding full-length BAG-1 protein (Takayama et al., 1995) was subcloned into a mammalian expression plasmid pcDNA3 containing a neomycin resistant gene, and were introduced into B16-BL6 cells that are capable of metastasizing to lungs by implantation into the subcutis or direct inoculation into blood vessels . After selection in neomycin, the Bcl-2 or BAG-1 transfectant cells were analysed by immunoblotting using Bcl-2 and BAG-1-speci®c anti-peptide antibodies. Elevated levels of Bcl-2 protein were detected in the B16-Bcl-2 transfectants but not those in the B16-NEO transfectants that received the pcDNA3 parental control plasmid ( Figure 1a) . The B16-Bcl-2 transfectants showed higher expression levels of Bcl-2 proteins than a human gastric cancer cell line, MKN45 expressing Bcl-2 protein highly ( Figure 1a ). Although BAG-1 expression was seen in B16-BL6 cells and the B16-NEO transfectants, markedly elevated level of BAG-1 protein was found in the B16-BAG-1 transfectants as compared with the B16-NEO transfectants ( Figure 1a) .
We next explored the ability of Bcl-2 or BAG-1 to drive cell proliferation in B16-BL6 cells. When the transfectants were cultured in MEM with 10% FCS, their growth curves showed no signi®cant dierence (Figure 1b) . Thus, overexpression of neither Bcl-2 nor BAG-1 proteins aected proliferation of B16-BL6 cells in vitro. In addition, the transfectants were inoculated subcutaneously in nude mice and the maximum diameters of their tumors were measured. They similarly produced subcutaneous tumors and their maximum diameters revealed no signi®cant dierence (Figure 1c) . Thus, overexpression of Bcl-2 or BAG-1 protein did not aect cellular growth of B16-BL6 melanoma cells either in vivo or in vitro.
Anti-cell death activity of B16-Bcl-2 and B16-BAG-1 transfectants
We analysed the relative sensitivity of the B16-Bcl-2, the B16-BAG-1 and the B16-NEO transfectants to serum-starvation. As shown in Figure 2 , the B16-Bcl-2 transfectants were resistant to serum-starvation, and gene transfer-mediated elevations in BAG-1 protein resulted in partial resistance to serum-starvation. At 3 days after serum-starvation, cell viability (% of control cells) of the B16-Bcl-2, the B16-BAG-1 and the B16-NEO was 67.7%, 44.6% and 20.7%, respectively ( Figure 2a) . We next examined cell morphology by staining nuclei of the transfectants with Hoechst 33342 with or without serum-starvation. Serum-starvation of 6 viable transfectants were inoculated subcutaneously into BALB/c nude mice. Maximum diameters of the tumor sizes were measured for the days indicated. Data represented the mean+standard deviation of three independent experiments of B16-Bcl-2 (triangle), B16-BAG-1 (square) and B16-NEO (diamond icon). Using the Student's ttest, no signi®cant dierences were seen among the transfectants for both in vitro and in vivo cell growth rates B16-NEO for 3 days induced apoptosis, which was characterized by nuclear fragmentation and chromatin condensation. In contrast, far fewer apoptotic cells were observed in cultures of the B16-Bcl-2 and the B16-BAG-1 transfectants (data not shown). Since CPP32/Yama (-like) proteases have been shown to play roles in driving apoptosis induced by a variety of stimuli (Fernandes-Alnemri et al., 1994; Darmon et al., 1995) , we next examined the enzyme activity of CPP32/ Yama, a member of the ICE protease family, in these transfectants following culture without serum for 1 to 5 days. Serum-starvation resulted in an increase in CPP32/Yama(-like) proteolytic activities, as assessed with a substrate for the CPP32/Yama protease, DEVD-MCA, by up to 370-fold in the B16-NEO transfectants for 3 days serum-starvation ( Figure 2b ). In contrast, serum-starvation resulted in signi®cantly less generation of CPP32/Yama(-like) proteolytic activities in both the B16-BCl-2 and the B16-BAG-1 transfectants, representing that up to 42% and 30% reductions, respectively, at 3 days after serum deprivation ( Figure 2b ). When YVAD-MCA was used as a substrate for ICE, signi®cantly less generation of ICE proteolytic activities was found and there was no signi®cant dierence among the transfectants. These data strongly suggest that overexpression of Bcl-2 or BAG-1 led to partial inhibition of apoptosis and CPP32-like protease activation induced by serumstarvation. Moroever, Bcl-2 overexpression endowed B16 cells a superior survival advantage compared with BAG-1 overexpression.
Metastatic potential of the B16-Bcl-2 and the B16-BAG-1 transfectants
To explore the correlation of anti-cell death activity with metastatic potential of B16 melanoma cells, the B16-Bcl-2, B16-BAG-1 and B16-NEO transfectants were injected into tail veins of nude mice, thus eliminating any possibility that any observed differences in metastatic potential were due to altered sensitivities to host T-cell-mediated immune responses. The representative lungs with pulmonary metastasis of each transfectant upon intravenous injection are shown in Figure 3a . Because of the extensive in®ltration of melanoma cells in the lungs, we evaluated their metastatic potential by comparison of the whole lungs' weights, which were increased by tumor colonization in lungs. The B16-Bcl-2 transfectants showed clearly elevated experimental metastasis by a 2.4-fold (2.4+0.4) increase of the weights compared with the B16-NEO transfectants, while the B16-BAG-1 transfectants showed slightly elevated metastasis by a 1.4-fold (1.4+0.3) increase of the weights (Figure 3b) , that is statistically signi®cant (P-value is 0.002). To exclude a possibility that B16-NEO aberrantly diminished metastatic ability, ability of spontaneous metastasis of parental B16-BL6 cells was compared with that of the B16-NEO transfectants. The mean average number of lung metastatic nodules produced by the B16-BL6 cells (2610 5 cells per mouse) was 17.4+3.5, while that by B16-NEO transfectants was 15.4+2.0, indicating that there was no signi®cant dierence in their metastatic ability (P-value is 0.45).
Similarly, overexpression of Bcl-2 protein enhanced pulmonary metastasis from subcutaneous tumors in the foot pads. The representative lungs with pulmonary metastasis of the B16-Bcl-2 and the B16-NEO transfectants upon subcutaneous inoculation (10 5 cells per mouse) are shown in Figure 4a . The mean average number of lung metastatic nodules produced by the B16-Bcl-2 transfectants was remarkably increased by 5.6-fold (5.6+1.2) compared with the B16-NEO transfectants (Figure 4b ). When larger numbers of Figure 2 Anti-cell death activity of transfectants against serum-starvation-induced apoptosis. (a) Superior resistance to serumstarvation in B16-Bcl-2 and B16-BAG-1 transfectants; transfectants were cultured for the indicated days at 5610 5 cells/ml in 0.2% FCS-MEM. The ability of the B16-Bcl-2 (triangle), B16-BAG-1 (square) and B16-NEO (diamond icon) transfectants to exclude trypan blue was assessed at the serum-deprivation. (b) B16-Bcl-2 (stippled and hatched bar) and B16-BAG-1 (hatched bar) transfectants delayed an increase of CPP32(-like) protease activity induced by serum-starvation in comparison with B16-NEO (stippled bar). In contrast, the same samples revealed much less ICE protease activity than CPP32(-like) protease activity and the ICE protease activity showed no signi®cant dierence among the transfectants. All data represent the means+standard deviations of three independent experiments cells were inoculated (10 6 cells per mouse), the mean average numbers of the nodules produced by the B16-Bcl-2 and the B16-BAG-1 transfectants were also increased by 3.2-fold (P-value is 50.0001) and by 1.7-fold (P-value is 0.02) compared with the B16-NEO transfectants (data not shown).
Cell motility and invasive ability of the transfectants
Cell motility and invasion potentiality are key elements for the accomplishment of cancer metastasis (Partin et al., 1989; . Many factors have been implicated as modulators of motility and invasion of tumor cells. We thus investigated whether overexpression of Bcl-2 or BAG-1 proteins may aect motility and invasion potentiality in the B16-Bcl-2 and the B16-BAG-1 transfectants. Using a gold-particle coating method (Albrecht-Buehler, 1977) , phagokinetic motilities of the B16-Bcl-2, the B16-BAG-1 and the B16-NEO transfectants were measured. The areas where the transfectants migrated lost gold-particles and the resultant open areas were thus visualized, indicating the area over which cells migrated. The areas of migration showed no signi®cant dierences among the transfectants (Figure 5a ), indicating that neither Bcl-2 nor BAG-1 protein overexpression aected motility. We next analysed the invasive potential of the transfectants using trans-well culture chambers coated with matrigel (Albini et al., 1987) . The numbers of transfectants that invaded into the lower chambers showed no signi®cant dierence. We therefore conclude that overexpression of neither Bcl-2 nor BAG-1 proteins had signi®cant eects on invasive potential (Figure 5b ). Though slight increases of cell motility and invasion potential were seen in the B16-Bcl-2 transfectants compared with the B16-BAG-1 and the B16-NEO transfectants, these dierences were not statistically signi®cant.
Cell viability in limiting-dilution cultures
During metastasis, cancer cells detach from the primary locations in the body and thus must survive without adequate cell-to-cell interactions. We thus examined the growth of the transfectants upon culturing limiting-dilution. One-hundred transfectants grown in medium containing 10% FCS were diluted and seeded into a 96 well plate with the medium supplemented with 2% FCS. After 5 day-culture, the numbers of wells containing a single colony were counted. The B16-Bcl-2 and the B16-BAG-1 transfectants exhibited enhanced growth in limiting-dilution cultures compared with the B16-NEO transfectants (approximately threefold and twofold increase, respectively) (Figure 5c ), suggesting that these transfectants may gain enhanced ability to survive without adequate cell-to-cell interactions. 
Discussion
We for the ®rst time provide evidence that prolonged cell survival promotes metastasis of a malignant melanoma cell line using gene transfer-mediated elevation in two anti-apoptotic proteins Bcl-2 and BAG-1. The B16-Bcl-2 and the B16-BAG-1 transfectants showed extensive pulmonary metastasis with signi®cantly higher rates of metastasis than control transfectants. Though both Bcl-2 and BAG-1 increased metastatic potential, the B16-Bcl-2 transfectants were more resistant to serum-deprivation-induced apoptosis than the B16-BAG-1 transfectants, and exhibited more extensive pulmonary metastasis than did the B16-BAG-1 cells. Thus, the resistance against apoptosis correlated with the promotion of pulmonary metastasis in B16-BL6 cells. This promotion of metastasis may be caused by biological activities related to overexpression of Bcl-2 or BAG-1 protein other than anti-cell death activity. However, these transfectants showed similar growth curves and produced subcutaneous tumors with similar sizes compared to B16-NEO control cells. In addition, their cellular motility and invasive ability were not signi®cantly dierent from the NEO controls. Thus, these data rule out possibilities that the promotion of metastasis by overexpression of Bcl-2 or BAG-1 proteins was due to the enhanced proliferation, motility or invasive ability.
Cell aggregation is also known to be another important factor for cancer cells to accomplish their metastasis (Raz and Lotan, 1987; Meromsky et al., 1986; Raz et al., 1990) . In this study, however, microscopical observation of the transfectants showed no signi®cant dierences of their cell aggregation capacities (data not shown), suggesting that differences in cell aggregation were at best ones marginally important for promotion of metastatic potential in the transfectants.
To approach a possible mechanism for enhanced metastasis of the B16-Bcl-2 and the B16-BAG-1 transfectants, we compared pulmonary metastasis of the transfectants upon intravenous injection with that upon subcutaneous inoculation. During passage through capillaries, cancer cells are subjected to apoptotic cell death by nitric oxide (NO) produced by activated vascular endothelial cells (Xie et al., 1995) . Prolonged cell survival thus can confer bene®cial to cancer cells in this step to proceed pulmonary metastasis. However, enhanced metastasis of B16 melanoma cells was similarly observed regardless of whether the transfectants were introduced by intravenous cell transfer or seeded as primary tumors made by subcutaneous inoculation. Thus, the promoted pulmonary metastasis of the transfectants introduced by enhanced anti-cell death activity may not be mainly due to resistance to NO-induced apoptosis.
We next compared cell survival upon culture at limiting dilution among the transfectants. To accomplish metastasis, cancer cells should survive without cell-to-cell interactions after detachment from a primary lesion. Our limiting dilution data strongly suggests that the B16-Bcl-2 and the B16-BAG-1 2 transfectants were diluted with MEM plus 2% FCS and seeded into 96 well dishes. The fractions of the well in which the transfectants grew were counted transfectants exhibited superior viability under conditions of serum-starvation and loss of cell-to-cell interactions, in comparison with control transfectants. Furthermore, the B16-Bcl-2 and the B16-BAG-1 transfectants also revealed superior viability when they were cultured in non-tissue culture petri dishes (data not shown). In these conditions, the transfectants could not attach to the dishes and thus their cell-to-cell interactions were extremely reduced. Considering that disruption of epithelial cell to matrix interactions leads to apoptosis (Boudreau et al., 1995; Ruoslahti and Reed, 1994) , which is strongly inhibited by overexpression of Bcl-2 (Frisch and Francis, 1994) , these data suggest that the B16-Bcl-2 and B16-BAG-1 transfectants may gain enhanced metastatic potential by reduced requirement of cell-to-cell interaction through enhanced anti-cell death activity.
Several studies argue levels of Bcl-2 expression in benign and malignant melanomas. Bcl-2 protein is highly expressed in benign melanocytes, but malignant melanomas mainly show decreased Bcl-2 expression (Tron et al., 1995; Sanez-Santamaria et al., 1994) , as shown here in B16-BL6 cells. However, some metastatic melanomas increase Bcl-2 expression (Tron et al., 1995) , and another report shows that metastatic malignant melanomas revealed higher Bcl-2 expression than other melanomas (Collins and White, 1995) . These data support our ®ndings, but also imply that other factors seem to be involved in metastasis of human malignant melanomas.
Our data provide at least two biologically and clinically signi®cant implications. First, the expression of apoptosis-regulating genes in cancer cells may provide useful markers for predicting metastatic potential and thus the existence of micrometastatic diseases. Secondary, our ®ndings suggest that therapies that can counteract the eects of anti-apoptotic proteins such as Bcl-2 and BAG-1 may prove ecacious for preventing tumor metastasis. This idea is supported by a recent work that a Bcl-2 related apoptosis-inducer Bax suppresses tumorigenesis (Yin et al., 1997) .
Materials and methods
Cell culture
Murine melanoma cell line B16-BL6 was generously provided from Dr I Fidler (MD Anderson Cancer Center, Houston, TX) and was maintained at a density of 0.2*1.5610 6 cells per ml in Minimum Essential Medium (MEM; GIBCO, Grand Island, NY) supplemented with 10% fetal calf serum (FCS). The B16-BL6 melanoma cells were selected in vitro for invasion through the urinary bladder wall, and produce pulmonary metastases above parental B16-F1 cells . B16-BL6 cells were cultured in MEM with either 10% or 0.5% FCS for 3 days and their cell viability was determined by staining with trypan blue.
Plasmid construction and DNA transfection
For the establishment of stable transfectants expressing bcl-2 or BAG-1, we used a pcDNA3 eucaryotic expression vector (Invitrogen, San Diego, CA). To construct pcDNA3-bcl-2, the full-length human bcl-2 gene pB4 (Tsujimoto and Croce, 1986) , kindly obtained from Dr Y Tsujimoto (Osaka University, Japan), was digested with EcoRI and then inserted into the EcoRI-cleaved pcDNA3 vector. To construct pcDNA3-BAG-1, the HindIII ± XbaI fragment of full-length murine BAG-1 gene (Takayama et al., 1995) was inserted into the HindIII ± XbaI-cleaved pcDNA3 vector. B16-BL6 cells were transfected with pcDNA3, pcDNA3-bcl-2 or pcDNA3-BAG-1 using Lipofection technique according to the manufacturer's Lipofection protocol (BRL). Selections were begun 3 days later using medium containing 0.7 mg/ml geneticin (GIBCO BRL). Individual clones were isolated and their characterization was investigated by Western blot analysis.
Antibodies and immunoblotting
B16-BL6 cells were washed with cold phosphate-buered saline (PBS) and lysed in 100 ml of a buer containing 100 mM NaCl, 2 mM EDTA, 10 mM sodium orthovanadate, 1 mM PMSF, 1% NP-40 and 50 mM Tris [pH 7.2]. Protein concentrations of the lysates were analysed by the Protein Assay kit (BioRad) and each lysate (50 mg/lane) was subjected to SDS ± PAGE, followed by electrophoretical transfer onto Immobilon (Millipore). The blots were incubated with blocking buer containing 3% BSA, 10 mM Tris [pH 8.2], 140 mM NaCl and 0.01% NaN 3 . Then, they were incubated with 1 mg/ml of anti-BAG-1 antibody described previously (Takayama et al., 1995) or anti-Bcl-2 antibody (DAKO) for 2 h in washing solution (150 mM NaCl, 10 mM Tris [pH 7.5] and 0.01% Tween 20) with 3% FCS, and the blots were developed by a standard enhanced chemiluminescence (ECL) method (Amersham). The blot was subsequently incubated with an anti-SHP-2 antibody and SHP-2 protein was detected to verify loading of equal amounts of total protein.
Tumorigenicity and experimental metastasis
To assess in vivo growth of transfectants, each transfectant (1610 6 cells per mouse) in 0.1 ml Hank's balanced salt solution (HBSS; GIBCO BRL) was inoculated subcutaneously in the¯ank region of nude mice (n=5). Their tumor sizes were monitored as their maximum diameter for 1 month. To assess pulmonary metastasis of the transfectants, the transfectants (1610 5 cells per mouse) in 0.1 ml HBSS were injected into the lateral tail veins of unanesthetized BALB/c nude mice. After 20 days, the lungs were removed from the mice, washed, and ®xed in neutralized 5% formaldehyde in PBS. The lung weights were measured and their metastasis was con®rmed by pathological examination. We also investigated their metastasis from the subcutaneous inoculation. Each transfectant (1610 5 cells per mouse) was subcutaneously inoculated in the left foot pad of nude mice and the legs with tumor were amputated 3 weeks after the inoculation. The visible metastasis in lungs, which was con®rmed by pathological investigation, was counted 2 weeks after the amputation.
Phagokinetic track motility assay
Cell motility of the transfectants was determined on the basis of phagokinetic tracks on a gold particle-coated plate as described previously. The colloidal-gold-coated coverslips were placed in 35 mm tissue culture dishes containing 2 ml MEM, and then 5610 3 freshly trypsinized cells were incubated for 24 h. The average areas cleared of gold particles by the cells were calculated.
Cell invasion assay
Based on the procedures as described, 1.5610 4 cells were cultured in upper compartment of 6 well BIOCOAT MATERIAL Invasion Chambers (Becton Dickinson, Bed-ford, MA) for 24 h and the cells, migrated through the polycarbonate membrane with an 8 mm pore and stuck to its lower surface, were counted under a microscope in 5 pre-determined ®elds at a magni®cation of 6200.
Measurement of CPP32(-like) protease activity
To evaluate apoptosis, 7-amino-4-methylcoumarin (AMC) assay for CPP32 protease activity was performed by the manufacturer's protocol with a minor modi®cation. The transfectants were cultured in MEM without FCS for 3 days and their total cell lysate was prepared with lysis buer (0.5 mM EDTA, 150 mM NaCl, 50 mM Tris-HCl and 0.5% NP-40). The 400 mg of lysates was incubated with 1 mM Ac-DEVD-MCA (a substrate of CPP32; Peptide Institute, Osaka, Japan) at 378C for 2 h. The same samples were also incubated with 1 mM Ac-YVAD-MCA (a substrate of ICE; Peptide Institute). Photometric measurements at 370 nm were carried out and amounts of released AMC were calculated.
Limiting dilution assay
To compare the colonization activity and cell viability under a solitary condition among transfectants, the 10 2 cells were plated with one cell per well in 96 well plates and cultured in MEM with 2% FCS for 10 days. Numbers of appeared colonies were counted.
